Roche, Novartis and Bayer snag NICE OKs

The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche ($RHHBY), Novartis ($NVS) and Bayer. Roche's Gazyvaro--a follow-up to Rituxan--has won the watchdog's blessing for patients with chronic lymphocytic leukemia, while Bayer snagged a thumbs up for high-flying eye med Eylea in diabetic macular edema and Novartis scored final NICE approval for next-gen psoriasis therapy Cosentyx. More

Read more on